Share Prices & Company Research

Stockbroking

Oxford Biomedica Plc

Current Price 622.00p Bid 620.00p Ask 624.00p Change 1.14%
Last Updated: 05/12/2025 08:55. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Oxford Biomedica develops innovative new IP-protected , LentiVector® based therapies, leveraging our internal research expertise and know-how. We select patient-centric product candidates and progress these through proof-of-concept, and into early clinical development, before either seeking third-party funding for full development and commercialisation or to develop further in-house.

Financial Highlights Year Ended 31/12/2024

Revenue
£128.80m
Operating Profit/Loss
£-39.38m
Dividend yield (%)
n/a
Total dividend for year
n/ap
Dividend cover
n/a
P/E Ratio
n/a
More Financials

Key Personnel

Dr Frank Mathias
Chief Executive Officer
Mr Lucinda (Lucy) Crabtree
Chief Financial Officer
Dr Heather Preston
Independent Non-Executive Director
Ms Namrata P Patel
Independent Non-Executive Director
Dr Roch Doliveux
Non-Executive Chairman
Mr Colin Bond
Non-Executive Director
Mr Dame Kay Davies
Non-Executive Director
Mr Peter Soelkner
Non-Executive Director
Ms Laurence Espinasse
Non-Executive Director

Stock Details

EPIC
OXBL
ISIN
GB0006648157
Shares in Issue
0.00m
Market cap
£0.00m

Price Summary

Mid Price
622.00p
Bid Price
620.00p
Ask Price
624.00p
Volume
0
Change Today
7.00p
% Change Today
1.14%
Open
625.00p
Previous Close
615.00p
Intraday High
649.50p
Intraday Low
615.00p
52 Week High
680.00p
52 Week Low
235.50p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

More Charts

News

Income Statement

Year End Date
31 Dec 2024
31 Dec 2023
 
£ (M)
£ (M)
Continuing Operations
Revenue
128.80
89.54
Operating Profit/Loss
-39.38
-184.17
Net Interest
-7.89
-14.17
Pre-Tax Profit
-47.27
-188.53
Profit After Tax from continuing operations
-48.61
-184.16
Discontinued Operations
Profit After Tax
n/a
n/a
Profit/Loss for the Year
-48.61
-184.16
Attributable to:
Equity Holders of Parent Company
-43.19
-157.49
Minority Interests
-5.42
-26.67
Total Dividend Paid
n/ap
n/ap
Retained Profit/(Loss) for the Financial Year
n/a
n/a

Earnings per Share

Year End Date
31 Dec 2024
31 Dec 2023
Basic
-41.75p
-163.11p
Diluted
-41.75p
-163.11p
Adjusted
-41.75p
-163.11p
Dividend per Share
n/ap
n/ap

Assets

Year End Date
31 Dec 2024
31 Dec 2023
 
£ (M)
£ (M)
Non-Current Assets
Property, Plant & Equipment
64.30
75.69
Intangible Assets
29.22
30.98
Investment Properties
n/a
n/a
Investments
n/a
n/a
Other Financial Assets
n/a
n/a
Other Non-Current Assets
4.93
4.34
Current Assets
Inventories
13.57
12.87
Trade & Other Receivables
58.97
24.74
Cash at Bank & In Hand
60.65
103.72
Current Asset Investments
n/a
n/a
Other Current Assets
n/a
n/a
Other Assets
n/a
n/a
Total Assets
231.64
252.34

Liabilities

Year End Date
31 Dec 2024
31 Dec 2023
 
£ (M)
£ (M)
Current Liabilities
Borrowings
4.42
3.65
Other Current Liabilities
53.90
40.66
Total Current Liabilities
58.32
44.31
Non-Current Liabilities
Borrowings
104.34
107.80
Provisions
8.44
8.55
Other Non-Current Liabilities
0.05
13.84
Total Non-Current Liabilities
112.84
130.19
Other Liabilities
n/a
n/a
Total Liabilities
171.16
174.51

Net Assets

Year End Date
31 Dec 2024
31 Dec 2023
 
£ (M)
£ (M)
Net Assets
60.49
77.83

Capital & Reserves

Year End Date
31 Dec 2024
31 Dec 2023
 
£ (M)
£ (M)
Share Capital
52.98
48.40
Share Premium Account
394.86
380.33
Other Reserves
8.71
-1.81
Retained Earnings
-399.50
-352.92
Shareholders Funds
57.05
74.01
Minority Interests/Other Equity
3.44
3.83
Total Equity
60.49
77.83

Dividend History

Dividend Metrics

Year End Date
31 Dec 2024
31 Dec 2023
Dividend growth
n/a%
n/a%
Dividend yield
n/a%
n/a%
Dividend cover
n/a
n/a


Cboe Global Markets® is a registered trade mark of Cboe Global Markets, Inc., a company incorporated in the United States of America with registered address at 400 South LaSalle Street, Chicago, IL 60605, USA. Cboe shall own any and all rights including without limitation Intellectual Property rights and any and all goodwill arising directly or indirectly out of the Recipient’s use of the “Cboe Global Markets®”, “Cboe®” and “Bats®”” trademarks. Neither Cboe nor its licensors accept any liability for any errors or omissions in the Cboe Europe Indices or underlying data. No further distribution of Cboe Europe data is permitted without Cboe’s express written consent.

The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.